Homocysteine inhibits neoangiogenesis in mice through blockade of annexin A2-dependent fibrinolysis

Journal of Clinical Investigation

Volumn 119, Issue 11, 2009, Pages 3384-3394

  Jacovina, Andrew T ^a   Deora, Arunkumar B ^a   Ling, Qi ^b   Broekman, M Johan ^a,c   Almeida, Dena ^a   Greenberg, Caroline B ^a   Marcus, Aaron J ^a,c   Smith, Jonathan D ^d   Hajjar, Katherine A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISULFIDE; FIBRIN; HOMOCYSTEINE; LIPOCORTIN 2; METHIONINE; PLASMIN; PLASMINOGEN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALYSIS; CONTROLLED STUDY; DERIVATIZATION; ENDOTHELIUM CELL; FIBRINOLYSIS; IN VITRO STUDY; MOUSE; NONHUMAN; NUTRITIONAL ASSESSMENT; PRIORITY JOURNAL; THROMBOCYTE FUNCTION;

ANIMALS; ANNEXIN A2; CELL MOVEMENT; CORNEAL NEOVASCULARIZATION; DIET; ENDOTHELIAL CELLS; FIBRIN; FIBRINOLYSIS; HOMOCYSTEINE; HYPERHOMOCYSTEINEMIA; MALE; METHIONINE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; RECOMBINANT PROTEINS;

EID: 70449428712     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI39591     Document Type: Article

References (65)

1. Hajjar, K.A. 2006. Vascular biology. In Clinical hematology. N.S. Young, S.L. Gerson, and K.A. High, editors. Mosby Elsevier. Philadelphia, Pennsylvania, USA. 123-133.
2. Cines, D.B., et al. 1998. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 91:3527-3561. (Pubitemid 28225719)
3. Levin, E.G., et al. 1997. The expression of endothelial tissue plasminogen activator in vivo: a function defined by vessel size and anatomic location. J. Cell Sci. 110:139-148.
4. Hajjar, K.A., et al. 1987. Binding of tissue plasminogen activator to cultured human endothelial cells. J. Clin. Invest. 80:1712-1719. (Pubitemid 18007146)
5. Hajjar, K.A., and Hamel, N.M. 1990. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. J. Biol. Chem. 265:2908-2916. (Pubitemid 20092410)
6. Hajjar, K.A. 1991. The endothelial cell tissue plasminogen activator receptor: specific interaction with plasminogen. J. Biol. Chem. 266:21962-21970. (Pubitemid 121000275)
7. Hajjar, K.A., Jacovina, A.T., and Chacko, J. 1994. An endothelial cell receptor for plasminogen and tissue plasminogen activator: I. Identity with annexin II. J. Biol. Chem. 269:21191-21197. (Pubitemid 24978790)
8. Gerke, V., and Moss, S.E. 2002. Annexins: From structure to function. Physiol. Rev. 82:331-371.
9. Gerke, V., Creutz, C.E., and Moss, S.E. 2005. Annexins: Linking Ca±± signalling to membrane dynamics. Nat. Rev. Mol. Cell Biol. 6:449-461. (Pubitemid 40780557)
10. Cesarman, G.M., Guevara, C.A., and Hajjar, K.A. 1994. An endothelial cell receptor for plasminogen/ tissue plasminogen activator: II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J. Biol. Chem. 269:21198-21203. (Pubitemid 24978791)
11. Ling, Q., et al. 2004. Annexin II is a key regulator of fibrin homeostasis and neoangiogenesis. J. Clin. Invest. 113:38-48. (Pubitemid 38541630)
12. Selhub, J. 1999. Homocysteine metabolism. Annu. Rev. Nutr. 19:217-246.
13. Jacobsen, D. 2001. Practical chemistry of homocysteine and other thiols. In Homocysteine in health and disease. R. Carmel and D. Jacobsen, editors. Cambridge University Press. New York, New York, USA. 9-20.
14. Nygard, O., et al. 1997. Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. 337:230-236. (Pubitemid 27310438)
15. Malinow, M.R., Bostom, A.G., and Krauss, R.M. 1999. Homocyst(e)ine, diet, and cardiovascular diseases: A statement for healthcare professionals from the nutrition committee, American Heart Association. Circulation. 99:178-182. (Pubitemid 29035977)
16. Pietrzik, K., and Bronstrup, A. 1997. Causes and consequences of hyperhomocyst(e)inemia. Int. J. Vitam. Nutr. Res. 67:389-395.
17. Moat, S.J., et al. 2004. Folate, homocysteine, endothelial function and cardiovascular disease. J. Nutr. Biochem. 15:64-79. (Pubitemid 38224347)
18. Splaver, A., Lamas, G.A., and Hennekens, C.H. 2004. Homocysteine and cardiovascular disease: Biological mechanisms, observational epidemiology, and the need for randomized trials. Am. Heart J. 148:34-40. (Pubitemid 38906645)
19. Markus, H.S. 2007. Genes, endothelial function and cerebral small vessel disease in man. Exp. Physiol. 93:121-127.
20. Ling, Q., and Hajjar, K.A. 2000. Inhibition of endothelial cell thromboresistance by homocysteine. J. Nutr. 130:373S-376S. (Pubitemid 30073753)
21. Hajjar, K.A., et al. 1998. Tissue plasminogen activator binding to the annexin II tail domain: direct modulation by homocysteine. J. Biol. Chem. 273:9987-9993.
22. Hajjar, K.A. 1993. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J. Clin. Invest. 91:2873-2879. (Pubitemid 23182548)
23. Hajjar, K.A., and Jacovina, A.T. 1998. Modulation of annexin II by homocysteine: implications for atherothrombosis. J. Investig. Med. 46:364-369.
24. Carmeliet, P. 2003. Angiogenesis in health and disease. Nat. Med. 9:653-660.
25. Risau, W. 1997. Mechanisms of angiogenesis. Nature. 386:671-674.
26. Werb, Z. 1997. ECM and cell surface proteolysis: Regulating cellular ecology. Cell. 91:439-442. (Pubitemid 27508232)
27. Loskutoff, D.J., and Quigley, J.P. 2000. PAI-1, fibrosis, and the elusive provisional fibrin matrix. J. Clin. Invest. 106:1441-1443.
28. Lijnen, H.R. 2001. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb. Haemost. 86:324-333. (Pubitemid 32663963)
29. Farrehi, P.M., Ozaki, K., Carmeliet, P., and Fay, W.P. 1998. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation. 97:1002-1008. (Pubitemid 28125473)
30. Fay, W.P., Parker, A.C., Ansari, M.N., Zheng, X., and Ginsburg, D. 1999. Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood. 93:1825-1830. (Pubitemid 29128482)
31. Konstantinides, S., Schafer, K., Thinnes, T., and Loskutoff, D.J. 2001. Plasminogen activator inhibitor-1 and its cofacor vitronectin stabilize arterial thrombi following vascular injury in mice. Circulation. 103:576-583. (Pubitemid 32116244)
32. Kurz, K.D., Main, B.W., and Sandusky, G. 1990. Rat model of arterial thrombosis induced by ferric chloride. Thromb. Res. 60:269-280.
33. Kenyon, B.M., et al. 1996. A model of angiogenesis in the mouse cornea. Invest. Ophthalmol. Vis. Sci. 37:1625-1632.
34. McCully, K.S. 1969. Vascular pathology of homocysteinemia: Implications for the pathogenesis of atherosclerosis. Am. J. Pathol. 56:111-128.
35. Humphrey, L.L., Rongwei, F., Rogers, K., Freeman, M., and Helfand, M. 2008. Homocysteine level and coronary heart disease incidence: A systematic review and meta-analysis. Mayo Clin. Proc. 83:1203-1212.
36. Maron, B.A., and Loscalzo, J. 2006. Homocysteine. Clin. Lab. Med. 26:591-609.
37. Eldibany, M.M., and Caprini, J.A. 2007. Hyperhomocysteinemia and thrombosis. Arch. Pathol. Lab. Med. 131:872-884.
38. Antoniades, C., Antonopoulos, A.S., Tousoulis, D., Marinou, K., and Stefanadis, C. 2009. Homocysteine and coronary atherosclerosis: From folate fortification to the recent clinical trials. Eur. Heart J. 30:6-15.
39. Hassan, A., et al. 2003. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain. 127:212-219. (Pubitemid 38055360)
40. Fassbender, K., et al. 1999. Homocysteine in cerebral macroangiography and microangiopathy. Lancet. 353:1586-1587.
41. Wong, A., et al. 2006. Hyperhomocysteinemia is associated with volumetric white matter change in patients with small vessel disease. J. Neurol. 253:441-447. (Pubitemid 43965608)
42. Khan, U., Hassan, A., Vallance, P., and Markus, H.S. 2007. Asymmetric dimethylarginine in cerebral small vessel disease. Stroke. 38:411-413. (Pubitemid 46184317)
43. Folstein, M., et al. 2007. The homocysteine hypothesis of depression. Am. J. Psychiatry. 164:861-867.
44. Selhub, J. 2008. Public health significance of elevated homocysteine. Food Nutr. Bull. 29:S116-S125.
45. Smith, D.A. 2008. The worldwide challenge of the dementias: A role for B vitamins and homocysteine? Food Nutr. Bull. 29:S143-S172.
46. Looker, H.C., et al. 2003. Homocysteine as a risk factor for nephropathy and retinopathy in Type 2 diabetes. Diabetologia. 46:766-772. (Pubitemid 36831404)
47. Schwartzfarb, E.M., and Romanelli, P. 2008. Hyperhomocysteinemia and lower extremity wounds. Int. J. Low. Extrem. Wounds. 7:126-136.
48. Castro, R., Rivera, I., Blom, H.J., Jakobs, C., and Tavares de Almeida, I. 2006. Homocysteine metabolism, hyperhomocysteunaemia and vascular disease: an overview. J. Inherit. Metab. Dis. 29:3-10.
49. Abahji, T.N., et al. 2007. Acute hyperhomocysteinemia induces microvascular and macrovascular endothelial dysfunction. Arch. Med. Res. 38:411-416.
50. Undas, A., et al. 2006. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler. Thromb. Vasc. Biol. 26:1397-1404. (Pubitemid 44305388)
51. Colucci, M., et al. 2008. Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential. J. Thromb. Haemost. 6:1571-1577.
52. Sauls, D., Wolberg, A.S., and Hoffman, M. 2003. Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: Implications for the mechanism of thrombosis in hyperhomocysteinemia. J. Thromb. Haemost. 1:300-306.
53. Todd, A.S. 1964. Localization of fibrinolytic activity in tissues. Br. Med. Bull. 20:210-212.
54. Levin, E.G., and del Zoppo, G.J. 1994. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels. Am. J. Pathol. 144:855-861.
55. Levin, E.G., Osborn, K.G., and Schleuning, W.D. 1998. Vessel-specific gene expression in the lung: tissue plasmingen activator is limited to bronchial arteries and pulmonary vessels of discrete size. Chest. 114:68S.
56. Wojta, J., Hoover, R.L., and Daniel, T.O. 1989. Vascular origin determines plasminogen activator expression in human endothelial cells. Renal endothelial cells produce large amounts of single chain urokinase type plasminogen activator. J. Biol. Chem. 264:2846-2852. (Pubitemid 19057779)
57. Pepper, M.S., et al. 1993. Upregulation of urokinase receptor expression on migrating endothelial cells. J. Cell Biol. 122:673-684. (Pubitemid 23226684)
58. Wojtukiewicz, M.Z., Sierko, E., Klement, P., and Rak, J. 2001. The hemostatic system and angiogenesis in malignancy. Neoplasia. 3:371-384.
59. Velez-Carasco, W., Merkel, M., Twiss, C.O., and Smith, J.D. 2008. Dietary methionine effects on plasma homocysteine and HDL metabolism in mice. J. Nutr. Biochem. 19:362-370. (Pubitemid 351685662)
60. Kopp, H.G., et al. 2006. Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization. J. Clin. Invest. 116:3277-3299.
61. Nagashima, M., et al. 2002. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J. Clin. Invest. 109:101-110. (Pubitemid 34052546)
62. Moore, G.M., Goulet, F., and Sartorelli, A.C. 1992. Purification of annexin I and annexin II from human placental membranes by high performance liquid chromatography. Protein Expr. Purif. 3:1-7.
63. Khanna, N.C., Tokuda, M., and Waisman, D.M. 1987. Purification of three forms of lipocortin from bovine lung. Cell. Calcium. 8:217-228.
64. Hajjar, K.A., Guevara, C.A., Lev, E., Dowling, K., and Chacko, J. 1996. Interaction of the fibrinolytic receptor, annexin II, with the endothelial cell surface: essential role of endonexin repeat 2. J. Biol. Chem. 271:21652-21659. (Pubitemid 26293036)
65. Kenyon, B.M., Browne, F., and D'Amato, R.J. 1997. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. 64:971-978. (Pubitemid 27314772)